Structure Financial Statements From 2010 to 2024

GPCR Stock   38.70  0.68  1.79%   
Structure Therapeutics financial statements provide useful quarterly and yearly information to potential Structure Therapeutics American investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Structure Therapeutics financial statements helps investors assess Structure Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Structure Therapeutics' valuation are summarized below:
Market Capitalization
2.2 B
Earnings Share
(2.19)
There are over one hundred nineteen available fundamental trend indicators for Structure Therapeutics American, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check Structure Therapeutics' current fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction.
Check Structure Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Structure Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 247.8 K, Net Interest Income of 14.1 M or Depreciation And Amortization of 241.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.47. Structure financial statements analysis is a perfect complement when working with Structure Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Structure Therapeutics Correlation against competitors.

Structure Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets506.1 M482 M72.4 M
Slightly volatile
Short and Long Term Debt Total5.7 M5.5 M762.8 K
Slightly volatile
Total Current Liabilities26 M24.7 M4.3 M
Slightly volatile
Property Plant And Equipment Net8.8 M8.4 M1.2 M
Slightly volatile
Accounts Payable4.3 M4.7 M2.4 M
Slightly volatile
Cash136.3 M129.8 M23.8 M
Slightly volatile
Non Current Assets Total8.8 M8.4 M1.5 M
Slightly volatile
Non Currrent Assets Other42.8 K45 K236.7 K
Slightly volatile
Other Assets0.951.0244.1 K
Slightly volatile
Cash And Short Term Investments490.7 M467.3 M70 M
Slightly volatile
Common Stock Shares Outstanding40.3 M36.7 M36.8 M
Slightly volatile
Short Term Investments354.4 M337.5 M50.5 M
Slightly volatile
Liabilities And Stockholders Equity506.1 M482 M72.4 M
Slightly volatile
Non Current Liabilities Total4.1 M4.3 M13.9 M
Slightly volatile
Capital Lease Obligations5.7 M5.5 M762.8 K
Slightly volatile
Other Current Assets3.1 M6.3 M1.6 M
Slightly volatile
Total Liabilities27.6 M29.1 M18 M
Slightly volatile
Property Plant And Equipment Gross9.5 MM1.3 M
Slightly volatile
Total Current Assets497.3 M473.6 M71 M
Slightly volatile
Capital Stock14.7 K14 KK
Slightly volatile
Net Working Capital471.3 M448.9 M66.7 M
Slightly volatile
Short Term Debt1.5 M1.4 M214.3 K
Slightly volatile
Common Stock14.7 K14 KK
Slightly volatile
Property Plant Equipment1.2 M1.5 M590.3 K
Slightly volatile
Deferred Long Term Liabilities4.1 M3.9 M841 K
Slightly volatile
Current Deferred Revenue284.8 K320.4 K348.9 K
Slightly volatile
Non Current Liabilities Other238.4 K268.2 K292 K
Slightly volatile

Structure Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision247.8 K236 K33.5 K
Slightly volatile
Depreciation And Amortization241.8 K316 K88.1 K
Slightly volatile
Interest Expense14.1 M13.4 M1.9 M
Slightly volatile
Selling General Administrative34.3 M32.7 M5.6 M
Slightly volatile
Other Operating Expenses107.9 M102.8 M17.6 M
Slightly volatile
Research Development73.6 M70.1 M12 M
Slightly volatile
Cost Of Revenue511.2 K949.2 K171.4 K
Slightly volatile
Total Operating Expenses107.9 M102.8 M17.6 M
Slightly volatile
Income Tax Expense247.8 K236 K33.5 K
Slightly volatile
Selling And Marketing Expenses782.1 K879.8 K958 K
Slightly volatile

Structure Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation8.6 M8.2 M1.8 M
Slightly volatile
Change In Working Capital7.3 MM1.2 M
Slightly volatile
Begin Period Cash Flow36.1 M26.1 M11.2 M
Slightly volatile
Depreciation996.6 K949.2 K162.9 K
Slightly volatile
Capital Expenditures2.3 M2.2 M306.3 K
Slightly volatile
Issuance Of Capital Stock495.9 M472.3 M66.7 M
Slightly volatile
Total Cash From Financing Activities473.7 M451.1 M63.6 M
Slightly volatile
End Period Cash Flow136.3 M129.8 M19.5 M
Slightly volatile
Change To Netincome1.6 M2.2 M956.6 K
Slightly volatile
Change To Liabilities1.9 M2.5 M1.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation2.172.28111.4514
Slightly volatile
Payables Turnover0.210.20020.049
Slightly volatile
Cash Per Share13.3612.72252.0233
Slightly volatile
Days Payables Outstanding1.7 K1.8 K21.2 K
Slightly volatile
Income Quality0.70.88690.8818
Slightly volatile
Net Debt To EBITDA1.851.21351.2456
Slightly volatile
Current Ratio10.3119.143412.5526
Very volatile
Graham Number27.3226.01854.2225
Slightly volatile
Capex Per Share0.06190.05890.0083
Slightly volatile
Debt To Assets0.01190.01130.0074
Pretty Stable
Days Of Payables Outstanding1.7 K1.8 K21.2 K
Slightly volatile
Ebt Per Ebit1.060.86970.9862
Very volatile
Quick Ratio10.3119.143412.5526
Very volatile
Net Income Per E B T1.11.00261.0137
Slightly volatile
Cash Ratio8.185.24626.1173
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.821.02730.9935
Slightly volatile
Debt Ratio0.01190.01130.0074
Pretty Stable

Structure Fundamental Market Drivers

Cash And Short Term Investments467.3 M

Structure Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Structure Therapeutics Financial Statements

Structure Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Structure Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Structure Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Structure Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue320.4 K284.8 K
Cost Of Revenue949.2 K511.2 K

Pair Trading with Structure Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Structure Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Structure Stock

  0.39DRMA Dermata TherapeuticsPairCorr
The ability to find closely correlated positions to Structure Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Structure Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Structure Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Structure Therapeutics American to buy it.
The correlation of Structure Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Structure Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Structure Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Structure Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Structure Stock Analysis

When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.